Yie-Ri Yoo

Yie-Ri Yoo

Auto-generated profile, based on publicly available information

Yie-Ri Yoo

Cancer Research Institute, Seoul National University, Seoul, Korea

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 September 2025 in Cancers
Verified
Journal Article
Open access
KJKyoungyun Jeong
Kyoungyun Jeong
AKAnnie Eunhee Koo
Annie Eunhee Koo
JYJaeun Yoo
Jaeun Yoo
JSJi-Yeon Shin
Ji-Yeon Shin
LLLeena Lim
Leena Lim
HLHyuk-Joon Lee
Hyuk-Joon Lee
Purpose: Near-infrared fluorescence-guided surgery (FGS) using cancer-specific tracers is promising for tailored gastric cancer (GC) surgery. Carcinoembryonic antigen (CEA) is a potential target due to its high expression in various digestive cancers, including GC. Materials and Methods: SGM-101, a chimeric anti-CEA monoclonal antibody conjugated with the near-infrared dye BM-104, was evaluated in GC. CEA expression was identified in GC cell lines at the mRNA and protein levels. Xenograft models (MKN-45, SNU-16, SNU-668, 85As2mLuc) were established in mice and injected with SGM-101 or PBS. Biodistribution was monitored using in vivo fluorescence imaging. Tumors were further analyzed by immunofluorescence. In a peritoneal carcinomatosis model, 85As2mLuc cells were injected intraperitoneally, and tumors were evaluated by bioluminescence and fluorescence and histology. Results: MKN-45, SNU-16, and 85As2mLuc were CEA-positive, while SNU-668 was CEA-negative. Flow cytometry confirmed CEA expression: MKN-45 (98%), SNU-16 (85.6%), SNU-668 (6.42%) and 85As2mLuc (78.4%). SGM-101 selectively targeted CEA-expressing tumors, with fluorescence peaking at 48 h, and immunofluorescence verified localization in tumor cells. In the peritoneal models, SGM-101 enabled precise detection of CEA-positive tumors. Conclusions: This study provides the first evidence for the feasibility of SGM-101 in gastric cancer, demonstrating its novelty and translational potential as a cancer-specific imaging agent for fluorescence-guided surgery.

1 August 2026 in Korean Journal of Clinical Oncology
Verified
Journal Article
Open access
PDF file
YYYie-Ri Yoo
Yie-Ri Yoo
KJKyoungyun Jeong
Kyoungyun Jeong
JYJaeun Yoo
Jaeun Yoo
HKHyun Myong Kim
Hyun Myong Kim
JSJi-Yeon Shin
Ji-Yeon Shin
DPDo Joong Park
Do Joong Park
Purpose: Gastric cancer is a heterogeneous disease in which cancer stem cell-associated properties may contribute to tumor heterogeneity and progression. This study aimed to establish paired normal and tumor gastric organoids, characterize stemness-related gene expression, and explore its association with organoid formation.Methods: Normal and tumor tissues were obtained from 12 patients with advanced gastric cancer. A total of 28 independent organoid cultures were established from 24 tissue specimens (12 normal and 12 tumor), with selected serial strip specimens divided into segments and cultured independently. Expression of stemness-associated markers (AQP5, CD44, ALDH1A, STMN1, and SOX2) was evaluated by quantitative real-time polymerase chain reaction and compared according to tissue origin, histological subtype, and organoid formation status.Results: Normal organoids tended to exhibit higher CD44 expression, whereas tumor-derived organoids showed relatively higher ALDH1A expression, although these differences were not statistically significant. Margin-derived normal organoids tended to show higher expression of multiple stemness-associated markers than those derived from tissue adjacent to tumors. Diffuse-type organoids tended to show higher CD44 expression, whereas AQP5, ALDH1A, STMN1, and SOX2 tended to be higher in intestinal-type organoids. Organoid-forming cultures consistently showed higher stemness-marker expression than non-forming cultures, particularly among tumor-derived organoids.Conclusion: Stemness-associated gene expression varied according to tissue origin, histological subtype, and organoid formation status. Higher stemness-marker expression in organoid-forming cultures suggests a potential association between stemness-related programs and organoid-forming capacity.

1 August 2026 in Korean Journal of Clinical Oncology
Verified
Journal Article
Open access
PDF file
JYJaeun Yoo
Jaeun Yoo
HKHyun Myong Kim
Hyun Myong Kim
KJKyoungyun Jeong
Kyoungyun Jeong
YYYie-Ri Yoo
Yie-Ri Yoo
JSJi-Yeon Shin
Ji-Yeon Shin
HYHan-Kwang Yang
Han-Kwang Yang
Purpose: Gastric cancer is a major global health issue, especially in advanced stages with metastasis. However, anti-angiogenic treatments such as ramucirumab target vascular endothelial growth factor, yet the exact mechanisms behind hematogenous metastasis remain unclear. This study analyzed RNA sequencing data from TCGA to identify angiogenesis-related genes in metastatic gastric cancer.Methods: Patients were categorized into four metastasis types (non-metastasis, hematogenous, locoregional, and lymphatic) based on clinical data. cBioPortal was used to identify frequently mutated genes across five metastatic cancer studies. RNA sequencing and clinical data were obtained from the TCGA-STAD project. RNA expression levels were compared across metastasis groups using independent-samples t-tests, followed by false discovery rate adjustment for multiple comparisons.Results: RNA expression analysis was performed using a 132-gene analytical panel in the TCGA-STAD cohort. Among the 95-gene angiogenesis/metastasis-related genes represented in this panel, RAF1, ARID1A, ERBB3, FGFR3, BAP1, TSC2, and KDR showed nominal expression differences in comparisons involving the hematogenous metastasis group. None of these differences remained statistically significant after false discovery rate correction.Conclusion: In this exploratory analysis, several candidate genes with prior literature support showed nominal expression differences in comparisons involving hematogenous metastasis in gastric cancer. These findings are hypothesis-generating and require validation in independent cohorts and functional studies.

1 January 2026 in IEEE Journal of Translational Engineering in Health and Medicine
Verified
Journal Article
Open access
JKJisung Kim
Jisung Kim
JKJane C. Kim
Jane C. Kim
KJKyoungyun Jeong
Kyoungyun Jeong
JLJiseon Lee
Jiseon Lee
JSJiyeon Shin
Jiyeon Shin
HLHyuk-Joon Lee
Hyuk-Joon Lee